Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

Presentation TCT 2022

TCT 383: Effect of Adding a Novel Coating to the Next-Generation Watchman Device in a Challenging Experimental Animal Model

Presenter: Walid Saliba

September 18, 2022

Presentation Scripps 2016

LAA Closure for Stroke Prevention: Novel and Next Generation Devices

Presenter: Brian K. Whisenant

February 03, 2016

Presentation

Time to Cost-Effectiveness After Stroke Reduction Strategies in A-fib: Warfarin vs Novel Oral Anticoagulants (NOACs) vs Left Atrial Appendage (LAA) Closure

Presenter: Vivek Y. Reddy

December 13, 2015

Presentation TCT 2014

TCT 175: Preclinical Study of the Novel Generation of Watchman for Left Atrial Appendage Occlusion

Presenter: Josep Rodés-Cabau, Peter B Sick, Krzysztof Bartus, Dongming Hou

September 16, 2014

Presentation TCT 2014

Percutaneous Left Atrial Access Using the Novel CorQuest HeartXs Device

Presenter: Josep Rodés-Cabau, Carlos E. Ruiz, David L. Brown, Pedro Martinez-Clark

September 14, 2014

Presentation TCT 2014

Percutaneous Left Atrial Appendage Closure for Atrial Fibrillation: Where Are We Compared to New Drugs and Ablation

Presenter: Jose Luis Assad-Morell, Efrain Gaxiola, Matthew J. Price

September 13, 2014

Presentation LAA 2014

Novel Anticoagulants

Presenter: Michael D. Ezekowitz

July 17, 2014

Presentation LAA 2014

Novel LAA Closure Technologies on the Horizon

Presenter: Vivek Y. Reddy

July 17, 2014

Presentation TCT 2013

Case #3: LAA Closure With a Novel Device

Presenter: Wolfgang Bocksch

October 28, 2013

Presentation TCT 2013

Are Novel LAA Closure Devices (Beyond Watchman) Needed in Germany?

Presenter: Gerald Werner

October 28, 2013

Presentation TCT 2013

Are Novel LAA Closure Devices (Beyond Watchman) Needed in the USA?

Presenter: Saibal Kar

October 28, 2013

Presentation

Initial Experience with a Novel Percutaneous LAA Exclusion Device in Pts with A-fib, Increased Stroke Risk, and Contraindications to Anticoagulation

Presenter: A. Massumi

January 14, 2013

Advertisement

TCT 383: Effect of Adding a Novel Coating to the Next-Generation Watchman Device in a Challenging Experimental Animal Model

LAA Closure for Stroke Prevention: Novel and Next Generation Devices

Time to Cost-Effectiveness After Stroke Reduction Strategies in A-fib: Warfarin vs Novel Oral Anticoagulants (NOACs) vs Left Atrial Appendage (LAA) Closure

TCT 175: Preclinical Study of the Novel Generation of Watchman for Left Atrial Appendage Occlusion

Percutaneous Left Atrial Access Using the Novel CorQuest HeartXs Device

Percutaneous Left Atrial Appendage Closure for Atrial Fibrillation: Where Are We Compared to New Drugs and Ablation

Novel Anticoagulants

Novel LAA Closure Technologies on the Horizon

Case #3: LAA Closure With a Novel Device

Are Novel LAA Closure Devices (Beyond Watchman) Needed in Germany?

Are Novel LAA Closure Devices (Beyond Watchman) Needed in the USA?

Initial Experience with a Novel Percutaneous LAA Exclusion Device in Pts with A-fib, Increased Stroke Risk, and Contraindications to Anticoagulation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content